Is renal denervation an alternative or a complement to aldosterone antagonists in treatment of resistant hypertension?

    loading  Checking for direct PDF access through Ovid


The role of the sympathetic nervous system in the pathophysiology of hypertension, particularly in resistant hypertension, is substantiated by a huge body of experimental and clinical arguments. Despite that, very little evidence is available in favor of a major effect of peripheral blockade of sympathetic receptors in essential hypertension [1–3]. Thus, several new therapeutic strategies have focused on targeting the hyperactivation of the sympathetic nervous system through renal denervation (RDN) or other devices interfering with the baroreflex [4]. Despite encouraging early results, a recent meta-analysis [5] has concluded for an unsatisfactory effect of RDN, and there is still a lot of discussion as to the real long-term extent of the blood pressure (BP)-lowering effect of RDN, especially when compared to the BP-lowering effect of intensified drug treatment, particularly with aldosterone receptor antagonists.

Related Topics

    loading  Loading Related Articles